Abstract
Background: More than 50% of oncohematological patients suffer from pain syndrome, mostly originating from the bone, which often include nociceptive and neuropathic complaints. Tapentadol, a recently available treatment option for cancer pain, exerts a dual analgesic mechanisms (opioid and noradrenergic), allowing for a high clinical efficacy as well as for a reduction in adverse events compared to traditional opioids.
Aim: To explore the safety and efficacy of tapentadol as a suitable agent for the pain management in the setting of oncohematology.
Methods: Our observational study included 36 patients with basal pain intensity (NRS) ranging from 5 to 10. Tapentadol prolonged release (PR) was given at the initial dose of 50 mg BID and careful titrated according to the achieved pain control. Results. Tapentadol PR was given at the dosages ranging from 200 and 260 mg/day after a careful titration, allowed for a clinically (-7 points NRS) remarkable reduction of pain intensity without any significant side effects.
Conclusion: In oncohematological patients on pain, tapentadol PR was effective and well tolerated, so representing a suitable treatment option in this difficult setting.
Keywords: Hematology, hematological malignancies, pain, stromal cells, syndromes, tapentadol.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Tapentadol PR for Pain Syndromes in Real Life Patients with Hematological Malignancy
Volume: 14 Issue: 1
Author(s): Sara Grammatico, Claudio Cartoni, Maria T. Petrucci, Pasquale Niscola, Marco Giovannini, Laura Scaramucci, Andrea Tendas, Adriana Costa, Marta Chisini, Gregorio A. Brunetti, Giada Mastrogiacomo, Sara Kiflom, Romina Talone, Giorgia Annechini, Ida Carmosino, Erminia Baldacci, Giacomo S. Morano and Giovanna Palumbo
Affiliation:
Keywords: Hematology, hematological malignancies, pain, stromal cells, syndromes, tapentadol.
Abstract: Background: More than 50% of oncohematological patients suffer from pain syndrome, mostly originating from the bone, which often include nociceptive and neuropathic complaints. Tapentadol, a recently available treatment option for cancer pain, exerts a dual analgesic mechanisms (opioid and noradrenergic), allowing for a high clinical efficacy as well as for a reduction in adverse events compared to traditional opioids.
Aim: To explore the safety and efficacy of tapentadol as a suitable agent for the pain management in the setting of oncohematology.
Methods: Our observational study included 36 patients with basal pain intensity (NRS) ranging from 5 to 10. Tapentadol prolonged release (PR) was given at the initial dose of 50 mg BID and careful titrated according to the achieved pain control. Results. Tapentadol PR was given at the dosages ranging from 200 and 260 mg/day after a careful titration, allowed for a clinically (-7 points NRS) remarkable reduction of pain intensity without any significant side effects.
Conclusion: In oncohematological patients on pain, tapentadol PR was effective and well tolerated, so representing a suitable treatment option in this difficult setting.
Export Options
About this article
Cite this article as:
Grammatico Sara, Cartoni Claudio, T. Petrucci Maria, Niscola Pasquale, Giovannini Marco, Scaramucci Laura, Tendas Andrea, Costa Adriana, Chisini Marta, A. Brunetti Gregorio, Mastrogiacomo Giada, Kiflom Sara, Talone Romina, Annechini Giorgia, Carmosino Ida, Baldacci Erminia, S. Morano Giacomo and Palumbo Giovanna, Tapentadol PR for Pain Syndromes in Real Life Patients with Hematological Malignancy, Cardiovascular & Hematological Agents in Medicinal Chemistry 2016; 14 (1) . https://dx.doi.org/10.2174/1871525714666160405110833
DOI https://dx.doi.org/10.2174/1871525714666160405110833 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Immunotherapy in a Natural Model of Aβ Pathogenesis: The Aging Beagle
CNS & Neurological Disorders - Drug Targets Mesenchymal Stem Cell-Based Therapy for the Treatment of Type 1 Diabetes Mellitus
Current Stem Cell Research & Therapy Mevalonate Pathway and Human Cancers
Current Molecular Pharmacology A New Strategy to Target Acute Myeloid Leukemia Stem and Progenitor Cells Using Chidamide, a Histone Deacetylase Inhibitor
Current Cancer Drug Targets A Wnt-ow of Opportunity: Targeting the Wnt/β-Catenin Pathway in Breast Cancer
Current Drug Targets Targeting p73 - a Potential Approach in Cancer Treatment
Current Pharmaceutical Design Folate Targeted Solid Lipid Nanoparticles of Simvastatin for Enhanced Cytotoxic Effects of Doxorubicin in Chronic Myeloid Leukemia
Current Nanoscience AIDS-Related Kaposis Sarcoma: State of the Art and Therapeutic Strategies
Current HIV Research A Review of Pediatric Mediastinal Masses and Castlemans Disease
Current Pediatric Reviews Monoclonal Antibodies: A Target Therapy for Multiple Sclerosis
Inflammation & Allergy - Drug Targets (Discontinued) Lymphoproliferative Disorders and Chemokines
Current Drug Targets Protein Targeting Constructs in Alpha Therapy
Current Radiopharmaceuticals FK506 Binding Proteins as Targets in Anticancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Pharmacokinetics-Guided Dosing of 5-Fluorouracil for Precision Cancer Treatment: A Focus on Colorectal Carcinoma
Applied Clinical Research, Clinical Trials and Regulatory Affairs Use of Radiopharmaceuticals for Diagnosis, Treatment, and Follow-Up of Differentiated Thyroid Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Antivirals Used for Influenza Chemoprophylaxis
Current Medicinal Chemistry Viral and Non-Viral Approaches for Transient Delivery of mRNA and Proteins
Current Gene Therapy Clozapine Induced Eosinophilia in a Case of Schizoaffective Disorder
Current Psychopharmacology Recent Advances in Pretargeted Radioimmunotherapy
Current Medicinal Chemistry Pro- and Anti-Arrhythmic Effects of Anti-Inflammatory Drugs
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry